journal article·2022-05-11

Watson–Crick Base Pairing-Inspired Laser/GSH Activatable miRNA-Coordination Polymer Nanoplexes for Combined Cancer Chemo-Immuno-Photothermal Therapy

Jiulong Zhang, Xiaoyan Sun, Xiufeng Zhao, Lin Liu, Xin Cheng, Chunrong Yang, Haiyang Hu, Mingxi Qiao, Dawei Chen, Xiuli Zhao

ACS Applied Materials & Interfaces· Volume 14· Issue 18
Publisher page

Abstract

The tumor immunosuppressive microenvironment (TIM) greatly hindered the efficacy of cancer immunotherapy. Overexpressed indoleamine 2,3-dioxygenase-1 (IDO1) in tumor tissues plays a vital role in TIM generation, and downregulation of IDO1 expression may reverse TIM. Inspired by the Watson–Crick base-pairing rule, a versatile noncationic miRNA vector (miDAC@PDA) is developed for cancer immunotherapy. Doxorubicin (DOX), adenosine triphosphate (ATP), and copper ions (Cu2+) are coassembled into coordination polymer nanoparticles (DAC) and bind miRNA via the hydrogen bond interaction (miDAC) between adenine residues (ATP) and uracil residues (miRNA). Polydopamine (PDA) is deposited onto the surface of miDAC for photothermal therapy. miDAC@PDA can efficiently accumulate into tumor tissues for cellular uptake. Under laser irradiation and high intracellular GSH levels, the PDA shell of miDAC@PDA can dissociate from miDAC for miRNA release due to local hyperthermia. Cu2+-mediated GSH consumption and intracellular ATP release can amplify the DOX-based immunogenic cell death (ICD) cascade, together with miR-448-mediated IDO1 inhibition, and these versatile nanoplexes will not only restrain primary tumor growth but also display a remarkable abscopal effect on distant tumors. Collectively, our study provides a unique strategy for intracellular gene delivery and an inspirational approach for multimechanism cancer management.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Stress, Anesthesia, and Immune Response · Adenosine and Purinergic Signaling

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China

Department of Oncology, Affiliated Hongqi Hospital of Mudanjiang Medical College, Mudanjiang 157011, P. R. China

Department of Pharmacy, Shantou University Medical College, Xinling Road, No. 22, Shantou 515041, P. R. China

Funding

China Postdoctoral Science Foundation · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1016/j.bioactmat.2020.11.01610.1016/j.bioactmat.2020.11.016 ↗
2. 10.1002/anie.20200511110.1002/anie.202005111 ↗
3. 10.1016/j.jconrel.2021.07.03810.1016/j.jconrel.2021.07.038 ↗
4. 10.1002/anie.20150093410.1002/anie.201500934 ↗
5. 10.1021/acs.nanolett.0c0477810.1021/acs.nanolett.0c04778 ↗
6. 10.1002/advs.20217003810.1002/advs.202170038 ↗
7. 10.1016/j.jconrel.2021.02.03210.1016/j.jconrel.2021.02.032 ↗
8. 10.1016/j.biomaterials.2021.12079110.1016/j.biomaterials.2021.120791 ↗
9. 10.1016/j.actbio.2021.09.05210.1016/j.actbio.2021.09.052 ↗
10. 10.1002/smll.20180067810.1002/smll.201800678 ↗
11. 10.1016/j.cej.2020.12431410.1016/j.cej.2020.124314 ↗
12. 10.1021/acsnano.0c0676510.1021/acsnano.0c06765 ↗
13. 10.1021/acsnano.0c1076410.1021/acsnano.0c10764 ↗
14. 10.1038/nm152310.1038/nm1523 ↗
15. 10.1016/j.canlet.2018.08.02810.1016/j.canlet.2018.08.028 ↗
16. 10.1002/adfm.20190974510.1002/adfm.201909745 ↗
17. 10.1021/acsnano.0c0070810.1021/acsnano.0c00708 ↗
18. 10.1021/acs.nanolett.1c0020910.1021/acs.nanolett.1c00209 ↗
19. 10.1038/cdd.2013.7510.1038/cdd.2013.75 ↗
20. 10.1002/anie.20200860410.1002/anie.202008604 ↗
21. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
22. 10.1016/j.biomaterials.2020.11975510.1016/j.biomaterials.2020.119755 ↗
23. 10.1021/acs.nanolett.8b0272010.1021/acs.nanolett.8b02720 ↗
24. 10.1016/j.jconrel.2020.02.01110.1016/j.jconrel.2020.02.011 ↗
25. 10.1021/acs.nanolett.8b0356810.1021/acs.nanolett.8b03568 ↗
26. 10.1002/adma.20210218810.1002/adma.202102188 ↗
27. 10.1016/j.biomaterials.2021.12116710.1016/j.biomaterials.2021.121167 ↗
28. 10.1002/adfm.20200740210.1002/adfm.202007402 ↗
29. 10.1021/acs.nanolett.9b0230610.1021/acs.nanolett.9b02306 ↗
30. 10.1021/acsami.9b0956810.1021/acsami.9b09568 ↗
31. 10.1016/j.jconrel.2020.09.03510.1016/j.jconrel.2020.09.035 ↗
32. 10.1002/adma.20180300110.1002/adma.201803001 ↗
33. 10.1016/j.biomaterials.2021.12118010.1016/j.biomaterials.2021.121180 ↗
34. 10.1021/jacs.5b1018210.1021/jacs.5b10182 ↗
35. 10.1016/j.addr.2014.05.00910.1016/j.addr.2014.05.009 ↗
36. 10.1016/j.jconrel.2019.11.01010.1016/j.jconrel.2019.11.010 ↗
37. 10.1186/s40425-019-0691-010.1186/s40425-019-0691-0 ↗
38. 10.1002/smll.20180392610.1002/smll.201803926 ↗
39. 10.1016/j.biomaterials.2021.12112810.1016/j.biomaterials.2021.121128 ↗
40. 10.1016/j.msec.2019.11010310.1016/j.msec.2019.110103 ↗
41. 10.1002/adfm.20200973310.1002/adfm.202009733 ↗
42. 10.1002/smll.20170396810.1002/smll.201703968 ↗
43. 10.1021/nn500722y10.1021/nn500722y ↗
44. 10.1016/j.biomaterials.2021.12097010.1016/j.biomaterials.2021.120970 ↗
45. 10.1016/j.actbio.2016.12.02110.1016/j.actbio.2016.12.021 ↗
46. 10.1016/j.biomaterials.2021.12089710.1016/j.biomaterials.2021.120897 ↗
47. 10.1016/j.bioactmat.2020.04.00310.1016/j.bioactmat.2020.04.003 ↗
48. 10.1016/j.biomaterials.2021.12098510.1016/j.biomaterials.2021.120985 ↗
49. 10.1002/anie.20200778610.1002/anie.202007786 ↗
50. 10.1016/j.cej.2020.12462810.1016/j.cej.2020.124628 ↗